{"success":true,"data":{"pressRelease":{"id":"34685","rtpr_id":"nGNXx9St6","ticker":"XRTX","exchange":"","all_tickers":["XRTX"],"title":"XORTX Announces US$5 Million Public Offering","author":"Globe Newswire","published_at":"2026-05-14T11:00:04.828Z","article_body":"CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.\n(“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:\nANU), a late-stage clinical pharmaceutical company focused on developing\ninnovative therapies to treat gout and progressive kidney disease, announces\nthe pricing of a public offering of 2,659,574 common shares (“Common\nShares”) or common shares equivalents in lieu thereof (“Pre-Funded\nWarrants”) at an offering price of US$1.88 for gross proceeds of US$5\nmillion, prior to deducting placement agent’s fees and other offering\nexpenses (the “Offering”). The Pre-Funded Warrants have an exercise price\nof US$0.0001 per share, will be immediately exercisable, and will terminate\nonce exercised in full.\n\nThe Offering is expected to close on or about May 15, 2026, subject to\nsatisfaction of customary closing conditions, including the receipt of all\nnecessary regulatory approvals, including the approval of the TSX Venture\nExchange.\n\nE.F. Hutton & Co. is acting as exclusive placement agent for the Offering.\n\nThe securities described above are being offered pursuant to a registration\nstatement on Form F-1 (File No. 333-290512), which was declared effective by\nthe U.S. Securities and Exchange Commission (the “SEC”) on May 13, 2026.\nThe Offering is being made only by means of the prospectus forming part of the\neffective registration statement relating to the Offering. A final prospectus\nrelating to the Offering will be filed with the SEC. Copies of the final\nprospectus relating to the Offering may be obtained, when available, by\ncontacting E.F. Hutton & Co., 745 Fifth Avenue, 34(th) Floor and PH, New York,\nNY 10151, or by email at efhcapitalmarkets@efhutton.com. Investors may also\nobtain these documents at no cost by visiting the SEC’s website\nat https://www.sec.gov.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy nor shall there be any sale of these securities in any\nstate or jurisdiction in which such offer, solicitation or sale would be\nunlawful prior to registration or qualification under the securities laws of\nany such state or jurisdiction.\n\nAbout XORTX Therapeutics Inc.\n\nXORTX is a pharmaceutical company with three clinically advanced products in\ndevelopment: 1) our lead program XRx-026 program for the treatment of gout; 2)\nXRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute\norgan injury associated with respiratory virus infections. In addition, the\nCompany is developing XRx-225, a pre-clinical stage program for Type 2\ndiabetic nephropathy and recently acquired VB4-P5 program, which is currently\nat the pre-IND stage of development and targets both rare and prevalent forms\nof kidney disease. XORTX is working to advance products that target aberrant\npurine metabolism and xanthine oxidase to decrease or inhibit production of\nuric acid. At XORTX, we are dedicated to developing medications that improve\nthe quality of life and health of individuals with gout and other important\ndiseases.\n\nFor more information, please contact:\n\n Allen Davidoff, CEO    Nick Rigopulos, Director of Communications  \n adavidoff@xortx.com    nick@alpineequityadv.com                    \n +1 403 455 7727        +1 617 901 0785                             \n                                                                    \n\nNeither the TSX Venture Exchange nor Nasdaq has approved or disapproved the\ncontents of this news release. No stock exchange, securities commission or\nother regulatory authority has approved or disapproved the information\ncontained herein.\n\nForward Looking Statements\n\nThis press release contains express or implied forward-looking statements\npursuant to applicable securities laws. For example, XORTX is using\nforward-looking statements when it discusses the expected mix of securities\noffered, the timing of the closing of the Offering and the satisfaction of\ncustomary closing conditions of the Offering. These forward-looking statements\nand their implications are based on the current expectations of the management\nof XORTX only, and are subject to a number of factors and uncertainties that\ncould cause actual results to differ materially from those described in the\nforward-looking statements. The Offering may not occur, may be delayed or may\nbe completed with different terms than are currently contemplated. Except as\notherwise required by law, XORTX undertakes no obligation to publicly release\nany revisions to these forward-looking statements to reflect events or\ncircumstances after the date hereof or to reflect the occurrence of\nunanticipated events. More detailed information about the risks and\nuncertainties affecting XORTX is contained under the heading “Risk\nFactors” in XORTX’s Registration Statement on Form F-1 filed with the SEC,\nwhich is available on the SEC’s website, www.sec.gov (including any\ndocuments forming a part thereof or incorporated by reference therein), as\nwell as in our reports, public disclosure documents and other filings with the\nsecurities commissions and other regulatory bodies in Canada, which are\navailable on www.sedarplus.ca.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/9898c4f8-b373-438a-abfa-709c4372a061)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXx9St6","title":"XORTX Announces US$5 Million Public Offering","author":"Globe Newswire","ticker":"XRTX","created":"2026-05-14T11:00:04.828Z","tickers":["XRTX"],"exchange":"","article_body":"CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.\n(“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:\nANU), a late-stage clinical pharmaceutical company focused on developing\ninnovative therapies to treat gout and progressive kidney disease, announces\nthe pricing of a public offering of 2,659,574 common shares (“Common\nShares”) or common shares equivalents in lieu thereof (“Pre-Funded\nWarrants”) at an offering price of US$1.88 for gross proceeds of US$5\nmillion, prior to deducting placement agent’s fees and other offering\nexpenses (the “Offering”). The Pre-Funded Warrants have an exercise price\nof US$0.0001 per share, will be immediately exercisable, and will terminate\nonce exercised in full.\n\nThe Offering is expected to close on or about May 15, 2026, subject to\nsatisfaction of customary closing conditions, including the receipt of all\nnecessary regulatory approvals, including the approval of the TSX Venture\nExchange.\n\nE.F. Hutton & Co. is acting as exclusive placement agent for the Offering.\n\nThe securities described above are being offered pursuant to a registration\nstatement on Form F-1 (File No. 333-290512), which was declared effective by\nthe U.S. Securities and Exchange Commission (the “SEC”) on May 13, 2026.\nThe Offering is being made only by means of the prospectus forming part of the\neffective registration statement relating to the Offering. A final prospectus\nrelating to the Offering will be filed with the SEC. Copies of the final\nprospectus relating to the Offering may be obtained, when available, by\ncontacting E.F. Hutton & Co., 745 Fifth Avenue, 34(th) Floor and PH, New York,\nNY 10151, or by email at efhcapitalmarkets@efhutton.com. Investors may also\nobtain these documents at no cost by visiting the SEC’s website\nat https://www.sec.gov.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy nor shall there be any sale of these securities in any\nstate or jurisdiction in which such offer, solicitation or sale would be\nunlawful prior to registration or qualification under the securities laws of\nany such state or jurisdiction.\n\nAbout XORTX Therapeutics Inc.\n\nXORTX is a pharmaceutical company with three clinically advanced products in\ndevelopment: 1) our lead program XRx-026 program for the treatment of gout; 2)\nXRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute\norgan injury associated with respiratory virus infections. In addition, the\nCompany is developing XRx-225, a pre-clinical stage program for Type 2\ndiabetic nephropathy and recently acquired VB4-P5 program, which is currently\nat the pre-IND stage of development and targets both rare and prevalent forms\nof kidney disease. XORTX is working to advance products that target aberrant\npurine metabolism and xanthine oxidase to decrease or inhibit production of\nuric acid. At XORTX, we are dedicated to developing medications that improve\nthe quality of life and health of individuals with gout and other important\ndiseases.\n\nFor more information, please contact:\n\n Allen Davidoff, CEO    Nick Rigopulos, Director of Communications  \n adavidoff@xortx.com    nick@alpineequityadv.com                    \n +1 403 455 7727        +1 617 901 0785                             \n                                                                    \n\nNeither the TSX Venture Exchange nor Nasdaq has approved or disapproved the\ncontents of this news release. No stock exchange, securities commission or\nother regulatory authority has approved or disapproved the information\ncontained herein.\n\nForward Looking Statements\n\nThis press release contains express or implied forward-looking statements\npursuant to applicable securities laws. For example, XORTX is using\nforward-looking statements when it discusses the expected mix of securities\noffered, the timing of the closing of the Offering and the satisfaction of\ncustomary closing conditions of the Offering. These forward-looking statements\nand their implications are based on the current expectations of the management\nof XORTX only, and are subject to a number of factors and uncertainties that\ncould cause actual results to differ materially from those described in the\nforward-looking statements. The Offering may not occur, may be delayed or may\nbe completed with different terms than are currently contemplated. Except as\notherwise required by law, XORTX undertakes no obligation to publicly release\nany revisions to these forward-looking statements to reflect events or\ncircumstances after the date hereof or to reflect the occurrence of\nunanticipated events. More detailed information about the risks and\nuncertainties affecting XORTX is contained under the heading “Risk\nFactors” in XORTX’s Registration Statement on Form F-1 filed with the SEC,\nwhich is available on the SEC’s website, www.sec.gov (including any\ndocuments forming a part thereof or incorporated by reference therein), as\nwell as in our reports, public disclosure documents and other filings with the\nsecurities commissions and other regulatory bodies in Canada, which are\navailable on www.sedarplus.ca.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/9898c4f8-b373-438a-abfa-709c4372a061)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-14T11:00:04.90779571Z","server_sent_at_ms":1778756404907},"received_at":"2026-05-14T11:00:05.008Z","source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294730/0/en/XORTX-Announces-US-5-Million-Public-Offering.html"},"analysis":{"id":"24657","press_release_id":"34685","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["offering priced below market price","potential dilution"],"eventType":"offering","narrative":"XORTX Therapeutics announced a public offering of 2,659,574 common shares or Pre-Funded Warrants at an offering price of US$1.88, for gross proceeds of US$5 million.\n\nThe Pre-Funded Warrants have an exercise price of US$0.0001 per share, are immediately exercisable, and will terminate once fully exercised.\n\nE.F. Hutton & Co. is acting as the exclusive placement agent for the offering, which is expected to close on May 15, 2026, subject to regulatory approvals.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Dilutive offering priced below market -- watch for downward pressure."},"keyFigures":{"dealValueUsd":5000000,"offeringPrice":1.88,"sharesOffered":2659574},"quotedText":"","namedEntities":{"people":[{"name":"Allen Davidoff","role":"CEO"},{"name":"Nick Rigopulos","role":"Director of Communications"}],"products":["XRx-026","XRx-008","XRx-101","XRx-225","VB4-P5"],"companies":[{"name":"XORTX Therapeutics Inc.","ticker":"XRTX","relationship":"issuer"},{"name":"E.F. Hutton & Co.","relationship":"placement agent"},{"name":"TSX Venture Exchange","relationship":"regulatory body"},{"name":"Nasdaq","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"US$5 million","context":"gross proceeds of public offering"},{"amount":"US$1.88","context":"per-share offering price"},{"amount":"US$0.0001","context":"exercise price of Pre-Funded Warrants"}]},"materialImpact":{"score":4,"reasoning":"The offering is priced at $1.88 per share, which is below the current market price, indicating potential dilution. The company is raising $5 million, which is a significant amount for a small-cap biotech firm."},"tickerRelevance":{"others":[{"ticker":"TSXV: XRTX","relevance":"mentioned"},{"ticker":"Frankfurt: ANU","relevance":"mentioned"}],"primary":"XRTX"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"public offering","sectorWeight":"Health Care","householdBrandBoost":"none","marketCapAdjustment":"biotech"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":4,"narrative":"XORTX Therapeutics announced a public offering of 2,659,574 common shares or Pre-Funded Warrants at an offering price of US$1.88, for gross proceeds of US$5 million.\n\nThe Pre-Funded Warrants have an exercise price of US$0.0001 per share, are immediately exercisable, and will terminate once fully exercised.\n\nE.F. Hutton & Co. is acting as the exclusive placement agent for the offering, which is expected to close on May 15, 2026, subject to regulatory approvals.","key_figures":{"dealValueUsd":5000000,"offeringPrice":1.88,"sharesOffered":2659574},"named_entities":{"people":[{"name":"Allen Davidoff","role":"CEO"},{"name":"Nick Rigopulos","role":"Director of Communications"}],"products":["XRx-026","XRx-008","XRx-101","XRx-225","VB4-P5"],"companies":[{"name":"XORTX Therapeutics Inc.","ticker":"XRTX","relationship":"issuer"},{"name":"E.F. Hutton & Co.","relationship":"placement agent"},{"name":"TSX Venture Exchange","relationship":"regulatory body"},{"name":"Nasdaq","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"US$5 million","context":"gross proceeds of public offering"},{"amount":"US$1.88","context":"per-share offering price"},{"amount":"US$0.0001","context":"exercise price of Pre-Funded Warrants"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-14T13:01:22.625Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"small-cap","eventGravity":"public offering","sectorWeight":"Health Care","householdBrandBoost":"none","marketCapAdjustment":"biotech"}},"durationMs":518842,"modelName":"george-droid-qwen-72b"}}